ClinicalTrials.gg
CompletedNCT02778919Updated Jun 4, 2019

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

A Phase 2 interventional study of KLH-2109 and Placebo in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2016
with 1 other
Phase 2
5 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
9 of 10
Kissei Pharmaceutical Co., Ltd.

Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2016, is one of 5 in phase 2, and was the 5th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with endometriosis

Exclusion criteria

Exclusion Criteria:

  • Patients with hepatic, renal, or cardiovascular dysfunction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2

Study arms

  • Experimental
    KLH-2109, lowest dose

    Drug: KLH-2109 · Drug: Placebo

  • Experimental
    KLH-2109, low dose

    Drug: KLH-2109 · Drug: Placebo

  • Experimental
    KLH-2109, medium dose

    Drug: KLH-2109 · Drug: Placebo

  • Experimental
    KLH-2109, high dose

    Drug: KLH-2109

  • Placebo comparator
    Placebo

    First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels

    Drug: Placebo

  • Other
    Leuprorelin acetate

    Active reference

    Drug: Leuprorelin acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Change of average Numerical Rating Scale (NRS) score of pelvic pain

    Time frame: 12 weeks

Secondary outcomes

  1. Incidences of adverse events

    Time frame: 24 weeks

07

Study locations

1 site
  • Multiple Locations, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Mar 2018, 22 months.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2016
First posted
May 20, 2016
StartActual
May 9, 2016
Primary completionActual
Mar 23, 2018
CompletionActual
Mar 23, 2018
Last update
Jun 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02778919
Responsible party
Sponsor
First posted
May 20, 2016
Start date
May 9, 2016
Primary completion
Mar 23, 2018
Completion
Mar 23, 2018
Last update
Jun 4, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion